In this episode of the BioVentures Podcast, we sit down with Dr. Samir Jenkins, an AR Health Ventures Accelerator program (ARHVA) awardee. ARHVA is a new funding program aimed at supporting the commercialization of promising research projects at UAMS. Dr. Jenkins is focused on developing radiation-activated liposomes for targeted chemotherapy delivery, specifically using cisplatin. This approach aims to minimize the toxicity of chemotherapy to healthy tissues by releasing the drug directly at the tumor site in response to radiation, a technique that is not widely explored in current clinical applications. Jenkins has conducted initial tests demonstrating successful drugrelease upon radiation exposure and is in the process of refining the technology for further testing. Our conversation touches on the challenges of treating aggressive cancers, like lung and pancreatic cancer, and the potential benefits of localized drug delivery to improve treatment outcomes.